Cargando…
Successful treatment with crizotinib after alectinib-induced interstitial lung disease
Although alectinib is a well-tolerated and highly effective inhibitor of a second-generation anaplastic lymphoma kinase, special attention should be paid to the possibility of potentially severe and fatal adverse events such as interstitial pneumonia. We report a case of a patient with advanced non-...
Autores principales: | Zhu, Ning, Lin, Shanhong, He, Lei, Wang, Linfeng, Kong, Weiliang, Cao, Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411646/ https://www.ncbi.nlm.nih.gov/pubmed/34484794 http://dx.doi.org/10.1177/2050313X211042991 |
Ejemplares similares
-
Successful alectinib treatment after crizotinib‐induced interstitial lung disease
por: Fujiuchi, Satoru, et al.
Publicado: (2016) -
Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report
por: Duarte, Flávia Amaral, et al.
Publicado: (2021) -
Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
por: Di Marino, Pietro, et al.
Publicado: (2020) -
Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease
por: Xie, Xiaohong, et al.
Publicado: (2019) -
Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib
por: Taima, Kageaki, et al.
Publicado: (2017)